Navigation Links
BioElectronics Corporation Receives Major Orders From Italian Distributor
Date:5/5/2008

ActiPatch(TM) Chosen as A Safe and Effective Alternative to NSAIDs, Such As

Vioxx(R) and Celebrex(R)

FREDERICK, Md., May 5 /PRNewswire-FirstCall/ -- BioElectronics Corporation (Pink Sheets: BIEL), the maker of the ActiPatch(TM), a drug free anti-inflammatory patch, with an embedded battery operated microchip delivering weeks of continuous pulsed therapy for a nickel an hour, announced today it has received significant new orders from its Italian distributor, TSS Medical, (Tecnica Scientifica Service). TSS Medical has purchased this additional inventory to meet demand in Italy and other European Union counties. BioElectronics is seeing demand for its product increase significantly in Western Europe, which combined with expanding sales in the U.S. and other countries, is likely to drive quarterly revenues to record levels.

Andrew Whelan, President and CEO of BioElectronics Corp. comments, "These are exciting times for all of us at BioElectronics. We expect demand from Italy to increase over the coming months as the product is rolled out to pharmacies across the country. We have also expanded the relationship with our Italian partner to include distribution to additional areas in Europe for which we have now received an initial stocking order. Many Europeans are very interested in the drug-free nature of our products at a time when NSAIDs, such as Vioxx(R) and Celebrex(R), have been determined to have potentially serious cardiovascular side effects. We believe health consumers with pain and soft tissue injuries will continue to view our proven, state-of-the-art ActiPatch therapy as an effective alternative to pharmaceuticals."

About BioElectronics Corporation

Bioelectronics Corporation is the maker of the ActiPatch(TM). ActiPatch is a drug free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective patient friendly method to reduce soft tissue pain and swelling. ActiPatch is U.S. Government Food and Drug Administration (FDA) cleared for use in reducing edema (swelling) following blepharoplasty and has no known side effects. The product is also approved by Health Canada for the relief of pain in musculoskeletal complaints and is widely available in pharmacies across Canada. The European Union has also approved ActiPatch as a Class II pulsed electromagnetic medical device as have numerous other international regulatory agencies. Information on ActiPatch and BioElectronics Corp. is available at the following websites:

-- U.S. Consumer http://www.actipatchonline.com

-- Podiatry: http://www.pemfpodiatry.com

-- Plastic Surgery: http://www.plasticsurgery.com and http://www.makemeheal.com

-- German orthopedic foot & ankle: http://www.diesfussexperten.de

-- Italy and Switzerland: http://www.actipatch.it

-- BioElectronics Corp: http://www.bioelectronicscorp.com

Safe Harbor Statement

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies In light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the company has no control.

Vioxx(R) is a registered trademark of Merck & Company

Celebrex(R) is a registered trademark of Pfizer Inc

Media Contact:

Patricia Baker, The Big Picture Agency LLC

Voice: 413-623-0950 ext. 221, email: pbaker@bigpictureagency.com

Investor Relations Contact:

Joe Noel, Emerging Growth Research LLP

Voice: 925-922-2560, email: jnoel701@emerginggrow.com


'/>"/>
SOURCE BioElectronics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioElectronics Corporation Announces Singapore and Malaysia Sales
2. BioElectronics Corporation Announces Distribution Agreement With TSS Medical of Italy
3. BioElectronics Announces Canadian Retail Product Launch
4. BioElectronics Launches 1 Day Breast Augmentation Recovery Kit
5. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
9. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
10. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
11. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... May 26, 2016  Agriculture nutrients are in the ... Iowa is running their nitrate removal system ... Erie and coastal regions nationwide are painting ... this widespread issue. NECi Superior Enzymes, a ... Peninsula, developed a new, easy to use device that ...
(Date:5/26/2016)... ... 26, 2016 , ... After several promising treatments in Panama ... City of Knowledge in Panama, a 6 year-old Duchenne’s muscular dystrophy patient received ... year following FDA approval of a second application for a single patient, investigational ...
(Date:5/25/2016)... ... May 25, 2016 , ... Thailand’s Board of Investment’s ... in San Francisco. Located at booth number 7301, representatives from the Thai Government, ... discuss the Thai biotechnology and life sciences sector. , Deputy Secretary General ...
(Date:5/25/2016)... ... ... Scientists at the University of Athens say they have evidence that the variety of ... could lead to one good one. Surviving Mesothelioma has just posted an article on ... evaluated 98 mesothelioma patients who got a second kind of drug therapy ...
Breaking Biology Technology:
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/21/2016)... Unique technology combines v ... security   Xura, Inc. ... digital communications services, today announced it is working alongside ... customers, particularly those in the Financial Services Sector, the ... within a mobile app, alongside, and in combination with, ...
Breaking Biology News(10 mins):